Third Harmonic Bio (Third Harmonic Bio) Cash, Cash Equivalents, Marketable Securities : $262.83 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Third Harmonic Bio Cash, Cash Equivalents, Marketable Securities?

Third Harmonic Bio's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($273.89 Mil) to Dec. 2023 ($269.07 Mil) but then stayed the same from Dec. 2023 ($269.07 Mil) to Mar. 2024 ($262.83 Mil).

Third Harmonic Bio's annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($128.28 Mil) to Dec. 2022 ($288.88 Mil) but then declined from Dec. 2022 ($288.88 Mil) to Dec. 2023 ($269.07 Mil).

Third Harmonic Bio Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Third Harmonic Bio's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Third Harmonic Bio Cash, Cash Equivalents, Marketable Securities Chart

Third Harmonic Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

8.28

128.28

288.88

269.07

Third Harmonic Bio Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial								282.20	278.13	273.89	269.07	262.83

Third Harmonic Bio Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Third Harmonic Bio (NAS:THRD) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Third Harmonic Bio Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Third Harmonic Bio's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Third Harmonic Bio (Third Harmonic Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Third Harmonic Bio Inc (NAS:THRD) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

1700 Montgomery Street, Suite 210, San Francisco, CA, USA, 94111

Website

https://www.thirdharmonicbio.com

Third Harmonic Bio Inc is a clinical-stage company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases.. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.

Executives

Julie Person	officer: Chief Administrative Officer	C/O THIRD HARMONIC BIO, INC., 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Edward R. Conner	officer: Chief Medical Officer	501 CANAL BLVD., POINT RICHMOND TECH CENTER, RICHMOND CA 94804
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
David P Bonita	director, 10 percent owner	C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139